Altered gastrointestinal transit (GIT)

Altered gastrointestinal transit refers to a physiological state or symptom characterized by an abnormal rate of movement of food, liquids, and waste through the digestive system. It is not a specific molecular target (such as a receptor or enzyme) but rather a clinical manifestation or physiological parameter resulting from the dysfunction of the enteric nervous system, smooth muscle contractility, or hormonal signaling (NIH, 2022). Accelerated transit often leads to diarrhea and malabsorption, while delayed transit results in constipation or gastroparesis. Pharmacological intervention aims to normalize transit speed by targeting specific receptors that govern motility, such as the serotonin (5-HT) or opioid receptor families. For example, prokinetic agents like prucalopride accelerate transit in patients with chronic constipation, whereas antidiarrheal agents like loperamide slow transit to increase water absorption (Mayo Clinic, 2023). This physiological process is a critical endpoint in drug development for gastrointestinal and metabolic disorders, as well as a common site for adverse drug reactions.

Other names

Gastrointestinal motility disorderDysmotilitySlow transitRapid transitAbnormal intestinal motilityAltered bowel habit

Drugs modulate gastrointestinal transit by acting as agonists or antagonists on molecular targets such as 5-HT4 receptors, mu-opioid receptors, motilin receptors, or chloride channels to either accelerate or decelerate the movement of luminal contents (StatPearls, 2023; PMC5802619).